. 2021 Jun 1;15(6):e0009446.

doi: 10.1371/journal.pntd.0009446. eCollection 2021 Jun.

Ivermectin as a potential treatment for COVID-19?

Olivier Chosidow^{1

2}, Charlotte Bernigaud^{1

2}, Didier Guillemot^{3

4

5}, Bruno Giraudeau⁶, Anne Lespine⁷, Jean-Pierre Changeux⁸, Hervé Bourhy⁹, Marc Lecuit^{10

11}, Zahir Amoura¹²

Affiliations

¹ Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France.
² Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France.
³ Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France.
⁴ AP-HP, Paris-Saclay, Public Health, Medical Information, Clinical Research, Le Kremlin-Bicêtre, France.
⁵ Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.
⁶ UMR SPHERE Inserm U1246, Université de Tours, Université de Nantes, & INSERM CIC1415, CHRU de Tours, Tours, France.
⁷ INTHERES, Université de Toulouse, INRAE, ENVT, Toulouse, France.
⁸ Institut Pasteur CNRS UMR 3571 Department of Neuroscience and Collège de France, Paris, France.
⁹ Institut Pasteur, Lyssavirus epidemiology and neuropathology Unit, Paris, France.
¹⁰ Intitut Pasteur, Biology of Infection Unit, Inserm U1117, Paris, France.
¹¹ Université de Paris, Service des Maladies Infectieuses et Tropicales, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Institut Imagine, Paris, France.
¹² Sorbonne Université, Inserm UMR-S 1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Groupement hospitalier Pitié-Salpêtrière, service de médecine interne 2, Paris, France.

PMID: 34061842
PMCID: PMC8168910
DOI: 10.1371/journal.pntd.0009446

Ivermectin as a potential treatment for COVID-19?

Olivier Chosidow et al. PLoS Negl Trop Dis. 2021.

. 2021 Jun 1;15(6):e0009446.

doi: 10.1371/journal.pntd.0009446. eCollection 2021 Jun.

Authors

Olivier Chosidow^{1

2}, Charlotte Bernigaud^{1

2}, Didier Guillemot^{3

4

5}, Bruno Giraudeau⁶, Anne Lespine⁷, Jean-Pierre Changeux⁸, Hervé Bourhy⁹, Marc Lecuit^{10

11}, Zahir Amoura¹²

Affiliations

¹ Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France.
² Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France.
³ Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France.
⁴ AP-HP, Paris-Saclay, Public Health, Medical Information, Clinical Research, Le Kremlin-Bicêtre, France.
⁵ Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.
⁶ UMR SPHERE Inserm U1246, Université de Tours, Université de Nantes, & INSERM CIC1415, CHRU de Tours, Tours, France.
⁷ INTHERES, Université de Toulouse, INRAE, ENVT, Toulouse, France.
⁸ Institut Pasteur CNRS UMR 3571 Department of Neuroscience and Collège de France, Paris, France.
⁹ Institut Pasteur, Lyssavirus epidemiology and neuropathology Unit, Paris, France.
¹⁰ Intitut Pasteur, Biology of Infection Unit, Inserm U1117, Paris, France.
¹¹ Université de Paris, Service des Maladies Infectieuses et Tropicales, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Institut Imagine, Paris, France.
¹² Sorbonne Université, Inserm UMR-S 1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Groupement hospitalier Pitié-Salpêtrière, service de médecine interne 2, Paris, France.

PMID: 34061842
PMCID: PMC8168910
DOI: 10.1371/journal.pntd.0009446

No abstract available

PubMed Disclaimer

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interest: Dr Chosidow and Bernigaud reported acting as unpaid scientific advisor for Medicines Development for Global Health, Dr Chosidow being the principal investigator of the RCT “Dose-finding Study of Moxidectin for Treatment of Scabies” (NCT03905265). Dr Chosidow is the scientific head of Gale SCRATCH (NCT02407782) and Gale CRUSTED (NCT02841215), both RCTs supported by the French Ministry of Health, Programme Hospitalier de Recherche Clinique. The other authors have declared that no competing interests exist.

Cited by

Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
Dicks LMT, Deane SM, Grobbelaar MJ. Dicks LMT, et al. Probiotics Antimicrob Proteins. 2022 Apr;14(2):217-223. doi: 10.1007/s12602-022-09925-5. Epub 2022 Feb 25. Probiotics Antimicrob Proteins. 2022. PMID: 35218001 Free PMC article. Review.
Targeting COVID-19 (SARS-CoV-2) main protease through active phytocompounds of ayurvedic medicinal plants - Emblica officinalis (Amla), Phyllanthus niruri Linn. (Bhumi Amla) and Tinospora cordifolia (Giloy) - A molecular docking and simulation study.
Murugesan S, Kottekad S, Crasta I, Sreevathsan S, Usharani D, Perumal MK, Mudliar SN. Murugesan S, et al. Comput Biol Med. 2021 Sep;136:104683. doi: 10.1016/j.compbiomed.2021.104683. Epub 2021 Jul 24. Comput Biol Med. 2021. PMID: 34329860 Free PMC article.
The use of Ivermectin for the treatment of COVID-19: Panacea or enigma?
Onyeaka H, Tamasiga P, Agbara JO, Mokgwathi OA, Uwishema O. Onyeaka H, et al. Clin Epidemiol Glob Health. 2022 Jul-Aug;16:101074. doi: 10.1016/j.cegh.2022.101074. Epub 2022 Jun 8. Clin Epidemiol Glob Health. 2022. PMID: 35694631 Free PMC article. Review.
SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.
Kolawole OM, Tomori O, Agbonlahor D, Ekanem E, Bakare R, Abdulsalam N, Okojie O, Braide E, Uzochukwu B, Rafindadi A, Bello S, Shehu S, Gureje O, Lecky M, Onwujekwe O, Onyedum C, Ezike A, Bukbuk D, Ashir G, Anyaehie B, Amazigo U, Habib A, Ufere J, Azodoh N. Kolawole OM, et al. JAMA Netw Open. 2022 Oct 3;5(10):e2236053. doi: 10.1001/jamanetworkopen.2022.36053. JAMA Netw Open. 2022. PMID: 36219441 Free PMC article.

References

1. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL et al. et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384: 693–704. 10.1056/NEJMoa2021436 - DOI - PMC - PubMed
1. Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol. 2021;96: 471–9. 10.1002/ajh.26102 - DOI - PMC - PubMed
1. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021. March 29. 10.1038/s41591-021-01316-7 Epub ahead of print. - DOI - PubMed
1. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jorgensen CK et al. Barot E, et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One. 2021;16: e0248132. 10.1371/journal.pone.0248132 - DOI - PMC - PubMed
1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178: 104787. 10.1016/j.antiviral.2020.104787 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Ivermectin as a potential treatment for COVID-19?

Affiliations

Ivermectin as a potential treatment for COVID-19?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources